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Background: The high-risk strategy has been proven effective in preventing cardiovascular disease; however, the
population benefits from these interventions remain unknown. This study aims to assess, at the population level,
the effects of an evidence-based high cardiovascular risk management program delivered by village doctors in
rural China.
Methods: The study will employ a cluster-randomized controlled trial in which a total of 120 villages in five
northern provinces of China, will be assigned to either intervention (60 villages) or control (60 villages). Village
doctors in intervention villages will be trained to implement a simple evidence-based management program
designed to identify, treat and follow-up as many as possible individuals at high-risk of cardiovascular disease in
the village. The intervention will also include performance feedback as well as a performance-based incentive
payment scheme and will last for 2 years. We will draw two different (independent) random samples, before and
after the intervention, 20 men aged ≥ 50 years and 20 women aged ≥60 years from each village in each sample
and a total of 9,600 participants from 2 samples to measure the study outcomes at the population level. The
primary outcome will be the pre-post difference in mean systolic blood pressure, analyzed with a generalized
estimating equations extension of linear regression model to account for cluster effect. Secondary outcomes will
include monthly clinic visits, provision of lifestyle advice, use of antihypertensive medications and use of aspirin.
Process and economic evaluations will also be conducted.
Discussion: This trial will be the first implementation trial in the world to evaluate the population impact of the
high-risk strategy in prevention and control of cardiovascular disease. The results are expected to provide
important information (effectiveness, cost-effectiveness, feasibility and acceptability) to guide policy making for
rural China as well as other resource-limited countries.
Trial registration: The trial is registered at ClinicalTrials.gov (NCT01259700). Date of initial registration is
December 13, 2010.
Keywords: Cardiovascular disease, Prevention, Primary care, Village doctor, Rural health, China,
Cluster-randomized trial* Correspondence: ywu@georgeinstitute.org.cn
1The George Institute for Global Health at Peking University Health Science
Center, Beijing, China
9Peking University Clinical Research Institute, Beijing, China
Full list of author information is available at the end of the article
© 2014 Yan et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Yan et al. BMC Public Health 2014, 14:345 Page 2 of 8
http://www.biomedcentral.com/1471-2458/14/345Background
Over the last decade, the global burden of non-
communicable disease has increased dramatically [1].
Cardiovascular disease is the leading cause of death
and disability worldwide [2]. More than 80% of this disease
burden is now borne by low and middle income countries
highlighting the need for effective interventions that are
affordable, applicable and effective in these settings [3].
There are two widely recognized strategies for the
prevention of cardiovascular disease – the “high-risk”
strategy and the “population” strategy [4]. However,
the debate on which strategy is more effective and
cost-effective continues up to date [5,6]. The high-risk
strategy is the natural approach for medical practitioners
and is recommended by most clinical guidelines as the
main strategy for prevention [7-9]. These high risk strat-
egies such as blood pressure, cholesterol and glucose
lowering treatment, use of aspirin, and lifestyle counsel-
ing among high-risk individuals have been proven both
effective and cost-effective through large scale randomized
controlled trials, particularly for secondary prevention
among those with disease [7]. However, current available
studies on the population impact of high-risk strategies
were only estimates based on simulation models and pa-
rameters from previously published observational studies
and clinical trials [10]. There is a lack of evidence from
well-designed population-based trial to evaluate the popu-
lation benefits from implementing these high-risk strat-
egies, particularly in resource-poor settings. Population
impact measures can be used to estimate the effect of
preventive strategies and interventions on health outcomes
at the population level [11] and are therefore useful for
informing public health decision making [10].
Rural China is under-developed and has more limited
healthcare resources compared to urban areas [12,13].
Chinese rural healthcare system is a 3-level network com-
prising county hospitals, township healthcare centers and
village clinics, and is administrated by county bureaus of
health. It provides healthcare for about 700 million rural
residents of China, half of the country’s population. The
lowest level facility is the village clinic which typically
serves a population between 300 and 2500 residents.
The primary care health services are provided by “village
doctors” who are not qualified physicians by Western
standard but are healthcare workers with limited medical
training, basic equipment and a restricted pharmacopeia
[12,14]. However, the size of this primary care workforce
is substantial with an estimated 1.13 million across
China [15]. Strategies that enable this workforce to de-
liver appropriate cardiovascular care to those at high
risk have the potential to reduce the disease burden in
these resource-poor settings.
The aim of the present study is to assess the population
impact of a high-risk strategy focusing on identification ofpatients at high cardiovascular risk and provision of
evidence-based preventive therapies by village doctors.
This paper describes the design and rationale of this
large, cluster randomized trial.
Methods
Overall study design
This study is part of the China Rural Health Initiative,
a translational research program to evaluate, at the
population level, two evidence-based, practical, simplified,
low-cost interventions for prevention and control of
cardiovascular disease among 120 rural villages from 10
counties in 5 provinces in northern China. The overall
design of the China Rural Health Initiative is two paral-
lel cluster-randomized controlled trials conducted in
the same 120 villages but having different interventions
and outcomes. The Sodium Reduction Study adopts a
population-based strategy to reduce salt intake through
health education plus marketing a low-sodium salt substi-
tute while the Primary Care Providers Study uses a high-
risk strategy to improve primary care of patients with high
risk of cardiovascular disease. We randomly assigned the
villages into 4 groups (each having 30 villages): no inter-
vention, sodium reduction intervention only, primary care
intervention only, and with both interventions. Each study
has 60 villages in intervention and 60 villages in control.
The protocol of the Sodium Reduction Study has been
published previously [16]. We describe the design and
rationale of the Primary Care Provider study here.
Village doctors in the intervention villages will implement
the intervention program for identifying and managing pa-
tients with high cardiovascular risk after being trained and
certified by the study (see below for details) while the con-
trol villages will receive no intervention from the study and
will continue their practices as usual. The duration of inter-
vention is 2 years. The evaluation of the study includes
effectiveness, process and economic evaluations.
Study setting and participating villages
Five provinces and autonomous regions (Hebei, Liaoning,
Ningxia, Shanxi and Shaanxi) will be selected from northern
China, where cardiovascular mortality is higher [17-19]
and their distances to the study coordinating center in
Beijing are shorter than those in southern China. We will
then purposefully select two counties from each province
and 12 townships from each county giving a total of 120
townships. The two counties will be selected to broadly
represent the socioeconomic development of the province.
The 12 townships will be selected based on their willing-
ness to participate and proximity to county centers. In
order to reduce the risk of intervention contamination, only
one village from each township will be invited to participate
in the study. The village will not be selected at random but
rather on the basis of being located near township centers
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pating villages. At each administrative level, agreement
to participate in the study will be sought from relevant
authorities.
Randomization
Using a central computerized process, townships will be
randomly assigned to either intervention or control group
in a 1:1 ratio. Randomization will be stratified by county
in an effort to minimize confounding due to county-level
factors such as differing levels of economic development.
Intervention
The intervention program is designed to enable village
doctors to not only identify high-risk individuals but also
manage as many eligible individuals as possible so that
the population health benefit of the intervention can be
maximized. To achieve this goal, our intervention pro-
gram includes the following components:
1. Technical package for high-risk patient management
The technical package is developed to guide village
doctors on how to screen, identify, treat, follow up and
refer cardiovascular high-risk individuals during their
routine services. The four core technical procedures and
corresponding algorithms are given below.
1) Easy identification of high cardiovascular risk
individuals:
Village doctors will be required to identify high-risk
individuals opportunistically by screening all patients who
visit the village clinics for any reason. They will also be
encouraged to contact patients with existing diseases or
potentially at high risk based on their previous knowledge
of the patients to maximize screening.
Patients will be defined as at high risk if they meet one
or more of the following criteria:
 History of coronary heart disease or stroke, or
 Older age (men ≥50 years and women ≥60 years)
with history of diabetes, or
 Older age (men ≥50 years and women ≥60 years)
with measured systolic blood pressure (SBP)
≥160 mmHg.
This definition is based on estimated 10-year absolute
risks of a major cardiovascular disease event [20,21]. The
age cut-off points in the last two criteria are different for
men and women in keeping with the evidence of differential
cardiovascular risk according to both age and sex.
2) Evidence-based simple treatments:Once identified as at high risk, the following basic
treatments will be initiated accordingly.
 Initiate blood pressure lowering medications if
systolic blood pressure ≥140 mmHg and not on
blood pressure lowing medication, with low-dose
diuretics recommended as first-line therapy due to
its efficacy, safety, and low cost.
 Initiate low dose aspirin when SBP < 160 mmHg and
not contraindicated
 Provide lifestyle advices such as smoking cessation
for current smokers, reduction of dietary salt
consumption, weight loss, and physical activity, with
emphasis on the first two.
 Encourage use of other evidence-based medications
such as β-blockers, ACE-inhibitors or angiotensin
receptor blockers and statins, if appropriate and
affordable for patients.
3) Monthly follow-up
All identified high-risk patients will be followed-up
every month by the village doctor. At each visit, doctors
will measure blood pressure, titrate treatment accordingly,
provide lifestyle modification advice and monitor acute
symptoms or early signs of clinical events.
4) Timely referral
Patients will be referred to hospital if they are experien-
cing new cardiovascular events, severe acute symptoms, or
if their condition becomes too serious for village doctors to
manage in a rural community setting.
2. Training of village doctors and use of assisting tools
Village doctors in intervention villages will be trained
using a “train the trainer” model. Cardiologists or general
physicians will be selected by county-level health bureaus
from the regional county hospital to attend a 2-day train-
ing course conducted in Beijing. These physicians will
then train the village doctors in their respective counties
in two one-day structured sessions, once before the inter-
vention and then again approximately one month after
initiation of the intervention. At the end of each training
session, all participants will be required to pass an exam-
ination to become ‘certified’ in the identification and man-
agement of cardiovascular high risk.
A number of tools will be developed to assist village
doctors to implement the standardized management
package. A village doctor manual will be developed and
provided to village doctors with detailed information
on clinical practice procedures, algorithms, medications
and standard dosages, etc. to assist the identification,
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cardiovascular disease. Standard case management forms
will also be developed and distributed to village doctors
for documenting initial and subsequent patient visits with
demographic information, history of disease, medical treat-
ments, lifestyle advice and blood pressure measurements.
The summary illustration of the technical procedures and
algorithms (Figure 1) will be printed as a 1×1.5 m large
colored wall poster and each doctor will be equipped with
an electronic sphygmomanometer.
3. Performance feedback
Village doctor performance data from case management
records for each patient visit and monthly follow-up will
be collected by study staff and entered onto a secure, web-
based database from which performance reports will be
generated and fed back to village doctors at approximately
semi-yearly intervals. The reports will include eight pre-
specified key performance indicators (KPIs) relevant to im-
proved cardiovascular risk management. These indicators
are number of high risk patients identified, proportion of
patients on regular management, proportion of patients
with blood pressure under control, proportions of patients
given lifestyle advice, low dose diuretics as well as aspirin.
The definitions of KPIs are shown in Table 1.
4. Performance-based incentives to providers
In the current healthcare system in China, many of
the interventions in our study such as high-risk patient
identification and follow-up and lifestyle consultation are
not income-generating for village doctors. In addition, we
encourage the use of low-cost medications, which usually
have a lower profit margin than more expensive ones.
To compensate for village doctors’ time and to encourage
more preventive services, appropriate amount of KPI-based
incentives will be provided by the study to village doctors,
in collaboration with local health authorities. These KPIs
will also be integrated into village doctors’ annual perform-
ance review by their local health authorities.
Effectiveness evaluation
Participants
We will draw two independent, random samples of 40
participants from each participating village for the effect-
iveness evaluation, one sample for pre- and the other for
post-intervention surveys, to collect data for the outcomes
measurement. Total number of participants will be 4,800 at
each survey. Both pre- and post- intervention surveys will
be conducted in the same season from late September to
early November to minimize the variation due to seasonal
changes. The sampling frame will use the “village roster,”
which contains a complete record of all age-eligible adults(men ≥ 50 years and women ≥ 60 years) in the village.
Stratified sampling will be used to ensure that each sample
contains equal numbers of men and women. We will ex-
clude individuals who have a severe mental health disorder
or disabilities that prevent them from effective communica-
tion for interview or traveling to the village clinic, or are not
able to be exposed with enough time to the intervention
(living more than 4 months a year out of village).
Baseline and post-intervention survey
The baseline survey will be conducted before the
randomization to blind the study staff from the interven-
tion allocation. The second survey will be done after the
2 years of intervention initiation at the same season. Both
surveys will be carried out by a study team independent to
those involved in the intervention implementation, in-
cluding village doctors, local project officers, intervention
trainers and officials in the county bureau of health. All sur-
vey personnel will be trained by the Beijing coordination
center in a standardized way and certified through passing
a tailor-made examination to become eligible.
Blood pressure, weight, height and heart rate will be
measured and recorded by trained study personnel ac-
cording to standardized protocols. Blood pressure will be
measured using an automated electronic sphygmoman-
ometer certified by the European Society of Hypertension
International Protocol (Omron Intellisense HEM 7301 IT)
[22]. A standardized questionnaire, administered by trained
interviewers, will collect information on disease history,
lifestyle, medication use, and health care seeking behaviors.
Beijing coordination center staff and provincial coordina-
tors will jointly supervise the field work and will monitor
the accuracy and completeness of the surveys. Double entry
will be used to enter all survey data into Epidata databases
by independent professional data entry clerk.
Outcomes of effectiveness
The primary outcome for the study will be the difference
in mean SBP before and after the intervention. Secondary
outcomes will comprise the pre-post differences in indices
of clinical care including the proportion of participants (1)
receiving regular primary care (defined as monthly visit to
village doctor with measurement of blood pressure); (2)
receiving lifestyle advice on smoking cessation, reduction
in consumption of dietary salt and alcohol, weight control
and increasing physical activity; (3) receiving treatment
with any evidence-based blood pressure lowing drugs; and
(4) receiving treatment with low-dose aspirin.
Sample size
The study will be powered on the primary outcome of mean
SBP assessed at the individual level. Based on a sample
of 4,800 individuals in 120 clusters (townships/villages),
an intra-cluster correlation coefficient (ICC) of 0.02 and
Figure 1 Management algorithm for the identification, management, and follow-up of high-risk patients.
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has 80% power (with two-sided alpha = 0.05) to detect
a 1.6 mmHg net difference in pre-post change of SBP
and 90% power to detect a 1.9 mmHg net difference in
pre-post change of SBP between intervention and con-
trol arms.Statistical analysis
The primary analysis will be conducted at the individual
level. For the primary outcome of SBP, we will use a gener-
alized estimating equations extension of linear regression
model which can account for repeated measurements
on the same villages (not individuals), with exchangeable
Table 1 Key performance indicators
Key performance indicators Definition Duration of measurement
1. Total number of patients identified Cumulative number of patients correctly identified by the
village doctor
Whole duration of intervention
2. Proportion receiving regular management Proportion of high-risk patients being regularly managed
(with≥ 5 monthly follow-up records in the past 6 months)
by the village doctor in the indicated period
Every 6 months
3. Proportion of patients with blood
pressure under control
Proportion of patients with systolic blood pressure under
control (with≥ 5 monthly SBP <140 mm Hg) among
those with hypertension
Every 6 months
4. Proportion of patients on life style
modification advices
The proportion of patients with case management record
indicating the prescription of≥ 5 months both
“salt reduction” and “no smoking”
Every 6 months
5. Proportion of patients on diuretics Proportion of hypertensive patients with case management
records indicating the prescriptions of diuretics≥ 5 months
Every 6 months
6. Proportion of patients on aspirin Proportion of high-risk patients with case management
records indicating the prescriptions of aspirin≥ 5 months
Every 6 months
All indicators are based on the case management records (one record per clinical visit) that the village doctors will fill out for all high-risk patients.
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The model will also include a time effect (pre-post) and
its interaction with the intervention to test if the pre-post
changes are different between intervention and control
groups. Point estimates of SBP will be reported with 95%
confidence intervals. All analyses will be conducted ac-
cording to the principle of intention-to-treat. Secondary
outcomes will be analyzed using a similar strategy, but
logistic regression instead of linear regression will be
used for these binary outcomes.
Process evaluation
A formal process evaluation will be conducted immediately
after the post-intervention survey to gain an understanding
of the extent to which the intervention is implemented
as planned, to evaluate its potential sustainability and to
explore enablers and barriers of the intervention. Face-to-
face, in-depth interviews with key stakeholders such as local
investigators, study coordinators, government officials, pro-
ject officers, village doctors, and high-risk patients involved
in the program will be conducted by independent investiga-
tors in selected locations. A standard interview guide will
be developed and administered and all interviews will be
tape-recorded for later transcription and analysis.
Economic evaluation
An economic evaluation will be conducted to provide an
assessment of the cost-effectiveness of the intervention
strategy. Intervention costs will be extracted from finan-
cial statements from the project and partner organiza-
tions. Patient-level costs including direct and indirect
medical costs, productivity loss, and health-related quality
of life will be obtained from a cohort of 300 men and
women, a random sample of 4,800 baseline survey partici-
pants, and the cohort will be followed up every 6 months
till the end of the study for collection of personal medicalcosts data. Cost effectiveness will be assessed, initially in
terms of cost per unit change in the primary and second-
ary outcomes, with additional modeling based on evidence
from the literature of disease progression and long-term
treatment effects.
Ethic approval
This study has been reviewed and approved by the
Institutional Review Boards of the Peking University
Health Science Center in Beijing, China and the Duke
University Health System in the US. Cluster-level consent
has been obtained through a consultation process involving
relevant provincial, county, township, and village authorities.
Written informed consent will be sought from all village
doctors (before allocation to intervention and control
villages) and from all individuals selected for the effective-
ness, process or economic evaluations
Discussion
To the best of our knowledge, this study is the first cluster-
randomized trial in the world to assess the population
impact of a high-risk strategy in prevention and control
of cardiovascular disease. The technical interventions used
are all evidence-based and tailored specifically for village
doctors. The study design is rigorous and innovative, with
large scale, sufficient power, cluster randomization, object-
ive outcomes assessment, independent pre- and post- ran-
dom samples of target population, blinded evaluation staff,
separation of intervention team and evaluation team, suffi-
cient quality control and assurance. The results of the study
will provide evidence on the population impact of a high-
risk strategy in prevention of cardiovascular disease and
help to resolve the dispute around high-risk strategy and
population strategy in prevention of cardiovascular disease
and other chronic diseases. As a late-stage translational
research project, it will also provide important information
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as well as possible barriers and drivers for implementation
of the low-cost, evidence-based program delivered by
village doctors in resource-constrained settings and thus
useful to guide policy making for prevention of cardiovas-
cular disease in low-resource countries and settings.
Close attention was paid to feasibility when designing
the intervention in this study. In rural areas, the primary
healthcare system is substantially under-resourced and
village doctors have minimal medical training. A complex
strategy for the diagnosis, assessment and management of
cardiovascular risk as recommended by most current
guidelines [25] (including lab-dependent risk stratification
algorithms) is therefore infeasible and unrealistic in rural
settings of China. The design of the trial is driven by the
need to find a simple, practical and cost-effective solution
to improving the management of cardiovascular disease in
this resource-limited setting. Village doctors will deliver
the intervention program because they are the only health
care providers in the villages. In addition, there is good
evidence that community healthcare workers can provide
effective care with adequate training and technical support
[26,27]. Further, the standard of practice provided by such
healthcare workers can be improved with interventions
that incorporate performance feedback and performance-
based incentives [28-30].
The interventions are also designed to be easily incorpo-
rated into existing health care policies and payment mech-
anisms for village doctors. Existing policies apply mainly
to the provision of curative services by village doctors and
do not extend to preventive care [31]. We therefore de-
signed a performance-based feedback and financial incen-
tive payment, which serves to address this gap. In 2009,
China launched a new nationwide health system reform
program [32]. Rigorous studies which evaluate the effects
of an evidence-based clinical management program deliv-
ered by village doctors in such settings are both important
and timely. If shown to be effective, the study may encour-
age Chinese health policy makers to consider an incentive
scheme which better caters to non-communicable disease
prevention and adopted as a part of the country’s current
health system reforms.
To ensure methodological rigor, we incorporated the
following design elements: first, we will select only one vil-
lage from each township to participate in the study. This
maximizes the distances between participating villages to
reduces the risk of contamination of intervention. Second,
to capture the effects of the intervention in improving both
the quantity of care (i.e. identification of high risk patients)
and the quality of care (i.e. evidence-based practices in
management of the high risk patients) and at the same
time avoiding cohort effect, we will select two independent
random samples – before and after intervention – in
all study villages in preference to a more conventionalcluster-randomized trial design of enrolling a fixed number
of high-risk patients in each village and following them up,
which will not allow us to evaluate the effect of the inter-
vention in improving the quantity of care. Such a design
of two independent random samples will also allow us to
evaluate the population impact of the intervention, which
is the primary aim and innovation of the study.
The evidence generated from the study is expected
to have significant implications for policy development
in China as a key objective of the current healthcare re-
forms is to strengthen primary health care [33]. Moreover,
the insights gained from this study will have broad applic-
ability to similar, resource-limited settings in other regions
of the world where providing effective care at lower cost
remains a universal challenge.
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